Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TYMP | P19971 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TK1 | P04183 | 3/20 | 0.46 |
| ▸ | TK2 | O00142 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14255480 | 0.84 | KMT2A (0.51) | MAPK1HPGDTYMPLMNAKMT2A | |
| SCHEMBL23328870 | 0.83 | TYMP (0.48) | MAPK1HPGDTYMPLMNAKMT2A | |
| SCHEMBL23328426 | 0.83 | MAPK1 (0.47) | MAPK1HPGDTYMPLMNAKMT2A | |
| SCHEMBL17013819 | 0.83 | MAPK1 (0.56) | MAPK1HPGDTYMPTK1 | |
| SCHEMBL18798676 | 0.83 | LMNA (0.68) | LMNAKMT2A | |
| SCHEMBL7643586 | 0.82 | MAPK1 (0.51) | MAPK1HPGDTYMPKMT2ATK1 | |
| SCHEMBL905269 | 0.82 | LMNA (0.49) | MAPK1HPGDTYMPLMNAKMT2A | |
| SCHEMBL456749 | 0.81 | HPGD (0.57) | MAPK1HPGDTYMPTK1TK2 | |
| SCHEMBL11983370 | 0.81 | MAPK1 (0.54) | MAPK1HPGDTYMPTK1 | |
| SCHEMBL452185 | 0.80 | MAPK1 (0.53) | MAPK1HPGDTYMPTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701333-B2 | Antibacterial compounds | Kent Innovation & Enterprise (GB) | 2023-07-18 | — | — | US | disclosed |
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | KENT INNOVATION & ENTERPRISE, UNIVERSITY OF KENT (GB) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701333-B2 | Antibacterial compounds | ARF1, ARL1, TLR1 | MAPK1 1432/4885HPGD 3179/4885TYMP 4515/4885 |
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | ARF1, ARL1, TLR1 | MAPK1 1432/4885HPGD 3179/4885TYMP 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.